Inhibition and deficiency of caspase-1 or nod-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome have shown benefits in regulating inflammation and outcomes in AD, experimental autoimmune encephalomyelitis (EAE), TBI, brain ischemia and Parkinson disease (PD) [10–14]. This evidence concerns the gene CASP1 and Alzheimer disease.